In order to face growing market demand for quality probiotic food supplements, Lallemand Health Solutions is investing in a brand new bacterial production plant in Mirabel, Canada. Using state-of-the-art equipment and production process, the new […]
Trace Genomics®, a San Francisco Bay area startup developing revolutionary, AI-enabled diagnostic tools for farmers to increase yields and reduce costs, has closed a $13 million Series A round. Trace Genomics has launched the first […]
Microbiotica, a leading player in microbiome-based therapeutics, announced that it has attracted an equity investment from Seventure Partners, a leading investor in the microbiome space. This new investment of £4m brings the total equity raised […]
ENTEROME SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company […]
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded three Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH), […]
Eagle Genomics announce partnership with Microsoft Genomics, a Microsoft Azure service dedicated to meeting the computational challenges of the genomics era. This is the first Microsoft partner focused in the microbiome genomics market. Microbiomics is […]
Synthetic Biologics, Inc. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, announced today the […]
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the appointment of Aoife Brennan, M.B., B.Ch., as president and chief executive officer of Synlogic, […]
Pivot Bio announced today $70 million in a Series B funding round led by Breakthrough Energy Ventures, and includes Singapore-headquartered investment company, Temasek. This funding further strengthens Pivot Bio’s 2019 commercial launch of the first […]
Following A-Mansia’s announcement of first close of Series A this April, Innovation Industries now joins the financing round of the microbiome company focused on developing products based on the unique properties of the Akkermansia muciniphila (A. […]
Second Genome, Inc., a clinical-stage company focused on the development of novel therapeutics identified through microbiome science, today announced the appointment of Karim Dabbagh, Ph.D., as president, chief executive officer, and a member of the […]